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Abstract

Hemophilia A is an X-linked disorder that results in uncontrolled bleeding, which is
caused by a lack of activity for blood coagulation factor VIII, an essential protein cofactor in the
clotting cascade. Factor VIII consists of multiple domains, and binding disruptions between
factor VIII and its circulatory partner, von Willebrand Factor, may cause von Willebrand disease.
Von Willebrand Disease type 2N is an autosomal recessive disease, and it is caused by binding
disruptions between the D’ domain (also known as TIL’E’) of von Willebrand Factor and a3
domain of factor VIII. A 2.9Å Cryoelectron microscopy structure of the FVIII:vWF complex
was recently published, and this crystal structure further described the interactions between
FVIII and vWF. To further understand the most severe types of von Willebrand Disease type 2N,
site-directed mutagenesis of vWF was employed to enhance the understanding of binding
disruptions between vWF and FVIII. The designed mutants were transformed, expressed, and
purified for further experimental studies. Binding assays were conducted between the mutants
against our bioengineered chimeric structure factor VIII, ET3i, via pull-down assays,
sedimentation assays, as well as quantitative studies via biolayer interferometry. The results of
this present study included the investigation of binding studies between the D’ domain of von
Willebrand factor and the a3 domain of factor VIII. The results obtained in this study were
interpreted, compared, and concluded to be consistent with the newest cryo-EM structure.
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Introduction

The layout of this thesis will be presented in five Chapters. Chapter one discusses the
overall physiological context of this research project. First, it will detail the blood coagulation
cascade in the traditional cascade as well as the improved cell-based model. This will include the
intrinsic pathway, extrinsic pathway, along with how disruptions of these pathways may cause
hemophilia. The primary hemophilia of interest, hemophilia A, along with von Willebrand
Disease will be presented. Lastly, the therapeutic treatments for these diseases will be presented.
Chapter two details the project’s protein of interest: first, factor VIII and von Willebrand
Factor (vWF) along with previous structural findings. Second, domains of von Willebrand factor
will be discussed, specifically, the D’ (TIL’E’) region. The binding mechanism and dissociation
from activated factor VIII of the D’ domain will be reviewed. Lastly, an anti-factor VIII antibody
will be introduced in this chapter, and their respective significance to factor VIII will be
described in the following chapters.
Chapter three describes the specific regions of factor VIII, C1, C2, and the A3 domain.
Structural studies will be presented along with their significance to the protein of interest; D’
domain of vWF. Next, mutations in vWF will be introduced along with the reason why these
mutants were chosen for study.
Chapter four details the progress towards the D’ domain of von Willebrand Factor along
with the mutants of this selected domain. Progress achieved in the lab include transformation,
protein expression via E.coli bacterial expression system, chromatographic purification methods,
as well as SDS-PAGE verification method. Additionally, binding studies will be detailed

between constructs of factor VIII and vWF. Lastly, the utilization of X-ray crystallography and
how it was applied in this study.
Chapter five tackles the results obtained via a series of various binding assays along with
X-ray crystallography. This final chapter will also detail the reaffirmation and discussion of the
current binding mechanism between vWF and factor VIII.
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Chapter 1

Introduction to Blood Coagulation

Upon vascular injury, there is a two-phased response termed “hemostasis” that is initiated to
prevent excessive blood loss and to preserve vital blood supply in the body. The first phase is
primary hemostasis, where the body initiates reduction of blood flow to the trauma site. Platelets
then aggregate at the vessel near the trauma site and form a “soft-plug”; this involves platelet
adhesion and platelet aggregation.1 This platelet rich “soft-plug” provides a surface for the
assembly of coagulation proteins during secondary hemostasis, where the “soft-plug” is
reinforced with a tough fibrin clot.
Secondary hemostasis deploys an activated thrombin in which it proteolytically attacks the
fibrinogen to form fibrin. The cross-linked fibrin will then form a clot across the trauma site to
prevent excessive bleeding.1 In order for secondary hemostasis to occur, it relies on a “waterfall”
event involving a network of proteins and a multitude of circulatory protein cofactors (factors IXIII) to create localized coagulation to the site of injury. This is known as the blood coagulation
cascade.2
The initially perceived single “waterfall” course, the blood coagulation cascade was
described in two pathways with a shared destination: the intrinsic and extrinsic pathways that
lead to the final common pathway.2 The common pathway leads to thrombin promoted insoluble
fibrin clot formation. The initially published description of the coagulation cascade was
perceived as a sequential cascade of protein interactions without consideration of extracellular
activity (Figure 1).2 During blood vessel injury, the extrinsic pathway is initiated from the
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exposed tissue factor (TF) protein that is expressed on the subendothelial cells that is
extravascular. The tissue factor protein activates factor VII (FVIIa), and the TF:FVIIa in the
presence of calcium activates factor X (FXa). The intrinsic pathway relies on activated Factor
XII (FXIIa) creating activated Factor XI (FXIa), which then activates factor IX (FIXa). On the
other hand, thrombin cleaves factor VIII (FVIII) which is circulating in the bloodstream in
complex with its carrier protein, von Willebrand Factor (vWF) to yield activated factor VIII
(FVIIIa). FVIIIa in complex with FIXa is known as the intrinsic tenase complex.2 The tenase
complex in the common pathway is composed of FXa:FVa which cleaves factor II (FII, also
known as prothrombin) to yield activated factor II (FIIa, also known as thrombin). In turn,
thrombin cleaves factor I (fibrinogen) into fibrin (FIa). Fibrin is cross-linked by activated factor
XIII (FXIIIa) to form stable fibrin clots (Figure 1).2
Unfortunately, this “waterfall” or cascade model described has been noted to be insufficient
in explaining the entire blood coagulation process, as the intrinsic and extrinsic pathway cannot
function independently to form a stable blood clot. Therefore, an improved cell-based model is
utilized to explain the coagulation cascade in detail. This model describes the cascade in three
distinct but intersecting phases: initiation, amplification, and propagation.3
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Figure 1. Flow schematic of the blood coagulation cascade (adapted from Davie and Ratnoff
1964).2 The traditional coagulation cascade portrays the intrinsic pathway and extrinsic
pathway converging to the final common pathway. The intrinsic pathway is initiated upon
blood vessel injury, which activates FVII. FXIIa then activates FXI to form the intrinsic
tenase complex (FXIIa:FXIa). The extrinsic pathway is stimulated by trauma, which activates
FVII. The TF:FVIIa complex along with the intrinsic tenase complex together activate FX.
This leads to the final common pathway, FXa forms the prothrombinase complex with FVa
(FXa:FVa) in the presence of calcium to generate large amounts of thrombin (FII). Fibrin is
then generated from fibrinogen to form a stable blood clot which is then deployed to the site
of injury to control excessive blood loss.
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Phase one: Initiation

Initiation- This is the first phase of hemostasis, traditionally known as the extrinsic pathway
of the coagulation cascade. This phase is stimulated by tissue damage, which results in the
expression of tissue factor protein on the surface of endothelial cells. Given this, the initiation
step is localized on tissue factor-presenting cells (e.g. fibroblast cells), which are extravascular.
Upon tissue damage, tissue factor along with circulatory proteases activate factor VII. FVII is
then exposed to the bloodstream. Then, FVIIa associates itself with its transmembrane receptor,
TF, forming the TF:FVIIa complex to activate factor IX in the presence of calcium (Figure 2).
Additionally, tissue damage causes platelet adhesion to other extracellular components which
increases the secretion of partially activated factor V.3 The activation of factor V can also be
achieved by thrombin, or activated factor X to form the extrinsic tenase complex (factor X:factor
V). The Tenase complex serves to convert prothrombin into thrombin, which functions as the
signal for platelet activation in this phase.
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Figure 2. Flow schematic of phase one of secondary hemostasis: initiation, also traditionally
known as the extrinsic pathway of the blood coagulation cascade (adapted from Davie and
Ratnoff 1964).2 In this phase, factor VII is activated via tissue damage. Tissue factor that’s
exposed on the cell surface binds to activated factor VII which then activates small amounts of
factor IX and factor X. Simultaneously, activated platelets bind to collagen along with other
extracellular matrixes to activate factor V. This leads to the factor X: factor V: tissue factor
complex known as prothrombinase. This complex produces small amounts of thrombin for the
next phase of hemostasis: amplification.

Phase Two: Amplification

Amplification- This is the second phase of hemostasis, which results in an increase level of
activated coagulation factors (Figure 3). The thrombin produced during the initiation phase then
activates factor V, factor VIII, and factor XI on platelet surfaces during this phase (resulting in
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factor Va, factor VIIIa, and factor XIa). The amplification phase sets the stage for the upcoming
large-scale production of thrombin in the propagation phase.3

Figure 3. Schematic of Phase two of the secondary hemostasis: Amplification (adapted from
Davie and Ratnoff 1964).2 In this phase, the levels of FVa, FXIa, FVIIIa, and activated platelets
are elevated from the small amounts of thrombin generated in the initiation phase. Elevated
levels of these factors are utilized in the third phase, propagation.

Phase Three: Propagation

Propagation- This is the final phase of hemostasis, contrary to the initiation phase, this is
traditionally known as the intrinsic pathway of the coagulation cascade. This phase is stimulated
by blood vessel damage and takes place on the surface of the activated platelets. In this stage, a
large influx of thrombin is produced to convert soluble fibrinogen into insoluble fibrin clots. In
order to do so, FVIIa activates FXIa which in turns activates FIXa allowing formation of the
8

intrinsic tenase complex (FVIIIa:FIXa). The intrinsic complex then activates prothrombinase
complex (FXa:FVa) generated in the initiation phase to produce an increased amount of
thrombin to proteolytically convert soluble fibrinogen into insoluble fibrin. These insoluble
fibrils are then gathered at the site of injury to form a stable, hard clot (Figure 4). The importance
of the improved cell-based model is to explain hemostasis in vivo, where the extrinsic FVIIa:TF
activated FX can’t compensate for the missing FVIII/FIX activity in hemophiliacs.3
The complete hemostasis process is complex and involves multivariable components, and
all components in secondary hemostasis play a crucial role in the success of a stable blood clot
formation. Any discrepancies within the complete hemostasis would result in coagulation
complication. However, the focus of this study will be on blood coagulation factor VIII. Factor
VIII plays a central role in the formation of the intrinsic tenase complex in the propagation
phase.
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Figure 4. The final phase of secondary hemostasis: propagation (adapted from Davie and Ratnoff
1964).2 This is also traditionally known as the intrinsic pathway of the blood coagulation
cascade. Propagation is initiated by blood vessel damage, or, vascular damage which activates
factor XII. Activated factor XII then activates factor IX which then forms the intrinsic tenase
complex, composing of activated factor XI, factor VIII, and platelets. The tenase complex then
activates factor X which is then utilized in forming the prothrombinase complex composing of
activated factor X, factor V, and activates platelets. The prothrombinase complex then generates
large scale thrombin production which then proteolytically converts soluble fibrinogen into
insoluble fibrin. The insoluble fibrin then accumulates into long fibrils and gather at the trauma
site to form a stable blood clot.
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Introduction to Blood Coagulation Factor VIII

Factor VIII is a glycoprotein that plays a critical role in the formation of a stable and
proper blood clot. FVIII is mostly synthesized in the hepatic sinusoidal cells.4 Mature FVIII is
initially synthesized as a multi-domain single polypeptide that consists of 2332 residues.
Domains of FVIII upon expression are as follows: A1-a1-A2-a2-B-a3-A3-C1-C2.5 The A
domains include short spacers (a1, a2, and a3), containing acidic regions with groups of
negatively charged amino acids: aspartic and glutamic acid. Additionally, the three A domains
have been found to have sequence homology to one another. Similarly, the two C domains have
significant homology to each other as well. Lastly, the B domain does not observe any homology
to other proteins. Previous studies have also indicated that the absence of B domain does not
affect FVIII functionality, and therefore undergoes proteolytic cleavage early in FVIII life cycle
at residues Arg1313 and Arg1648.5 This cleavage forms a noncovalent heterodimer consisting
two sectors: the heavy chain (A1-A2-B) and light chain (A3-C1-C2) (Figure5).5
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Figure 5. Schematic review of the construct of FVIII (adapated from Kauffman, 1988).6 FVIII is
initially synthesized in a single polypeptide consisting of 2332 residues (A1-a1-A2-a2-B-a3-A3C1-C2). The lower-case domains (a1, a2, and a3) are acidic linker regions to their respective
domains. FVIII cleavage occurs at residues Arg1313 and Arg1648 resulting in secretion out of
the cell as an inactive heterodimer. (A1-a1-A2-a2-B/ a3-A3-C1-C2). FVIII is then activated by
thrombin cleavage at Arg372, Arg740, and Arg1689.

FVIII circulates the bloodstream in its inactive form, noncovalently bound to its circulatory
partner, von Willebrand Factor. This interaction between the two glycoprotein prevents the
premature dissociation of FVIII in circulation as it is not stable if not in complex with vWF.
Additionally, this interaction is also thought to prevent premature binding of FVIII to FIXa along
with activated platelet surfaces.7,8
Previous studies show that two specific regions of the FVIII light chain is involved in
vWF binding: the acidic region of the A3 domain (residues 1649-1689) as well as the carboxy
terminus of the C2 domain (Figure 6).9 FVIII is only proteolytically activated into a heterodimer
upon activation. FVIIIa then dissociates from its circulatory partner, vWF, along with removal of
the acidic a3 region of FVIII.8–10 FVIIIa then binds to the activated platelet surfaces, and in the
presence of calcium ions, serves as a cofactor for serine protease FIXa. This complex is also
known as the intrinsic tenase complex and is responsible for large scale activation of FX.
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Figure 6. X-Ray Crystal Structure of bioengineered chimeric FVIII, ET3i. This is a B domain
deleted FVIII heterodimer composed of heavy chain (porcineA1- humanA2) and light chain
(porcine A3-C1-C2). C1 observes similar homology with C2, and the C domains have been
proposed to be involved in vWF binding (PDB ID 6MF2).11
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Hemophilia A

Hemophilia is a disorder that affects the body’s ability to maintain homeostasis by
forming stable blood clots. There are many forms of hemophilia. Briefly, the cause of
hemophilia A is the decreased activity of FVIII, the cause of hemophilia B is the deficiency of
functionality of FVIII, and the cause of hemophilia C is the deficiency of Factor XI (FXI) and
parahemophilia which is a deficiency of Factor V (FV). In this study, hemophilia A is the
primary disease of interest for discussion.
There are four DNA mutations that may take place, leading to hemophilia A: deletions,
insertions, inversions, and substitution. Each of these mutations may affect function, structural
integrity, or both. More specifically, protein sequence mutations can be classified as null,
truncation, or point. A null mutation results in complete loss of protein expression, or complete
absence of the protein of interest that is encoded by the gene. A truncation mutation may result in
only partial expression of target protein. Finally, a point mutation (substation) is where a specific
amino acid at a specific location change to another; this can have a significant impact on protein
function as well as structure. Mutations that take place in the binding domains of FVIII to vWF
may result in hemophilia A, specifically point mutations.
Hemophilia A is a blood clotting disorder that is caused by the lack of activity for the
protein cofactor (FVIII). Hemophilia A is a X-linked blood disorder that prevents proper blood
clot formation, and this disorder affects approximately one in every 5000 males.12 Hemophilia A
is characterized by excessive or prolonged bleeding episodes where a blood clot is unable to
properly form at the site of injury. The severity of this disorder is dependent on the degree of
dysfunctional FVIII present. Mild hemophilia A is defined with approximately 6-30% normal
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FVIII activity, moderate is categorized as 1-5% normal FVIII functionality, and severe with less
than 1% normal activity.13 The 186 kb gene coding of the FVIII protein (F8) is located on the
long arm of the X-chromosome, position 28.14 There are many different possible mutations
within the F8 gene that can heavily affect protein activity during coagulation. Acquired
hemophilia is another form of hemophilia that does not involve a genetic mutation basis.
Acquired hemophilia occurs when the body produces antibodies against FVIII which results in
rapid dissociation from its circulatory partner vWF and loss of function.

Hemophilia A Therapeutic Treatments

Replacement therapy is currently the most widely used method for Hemophilia A in the
United States. Replacement therapy consists of infusion of either direct plasma derived or
recombinant human FVIII (hFVIII) concentrates.15 These infusions can be utilized as episodic
infusions or as prophylactic treatments for severe hemophilia A. Episodic infusions refer to
replacement of hFVIII after each bleeding episode, to replenish FVIII and thereby stabilize the
bleeding episode. Prophylactic treatment on the other hand, refers to regular infusions (often two
to three times a week) of FVIII concentrates as hemorrhagic prevention, i.e., reduction in the
number of bleeding episodes and thereby improving the patient’s quality of life. The
disadvantage is that the patient will be required to visit their physician to receive these infusions
two to three times per week, which is a demanding schedule. These replacements aren’t always
mutually exclusive, i.e., on top of prophylactic replacement therapy, on-demand (plasma
derived) treatment is often utilized in emergency situations.
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Plasma derived hFVIII was first discovered and heavily utilized as the primary method
for hemophilia A treatment. In this method, FVIII is prepared by extracting along with
purification of the glycoprotein from cryoprecipitate prepared from human plasma.16 There are
complications associated with this method upon its initial discovery, and that is transmission of
viral containments and diseases. However, with improving technology and enhanced testing,
transmission of viral contamination has been eradicated. Additionally, technology has been
developed to advance disease detection prior to utilization of replacement therapy.17
Recombinant FVIII are primarily produced by Chinese Hamster Ovary (CHO) cells or Baby
Hamster Kidney (BHK) cells transfected with hFVIII gene.18 To ensure safety prior to infusion,
the concentrated proteins are subjected to viral inactivation methods.
Various recombinant FVIII products are available in the states; common recombinant
FVIII therapeutics include Xyntha by Pfizer, Advate by Baxter, and Kogenate FS by Bayer
Pharm. Doses of each of these products is based on the patient’s level of FVIII deficiency,
weight, and amount of bleeding. These products are usually injected intravenously via IV bolus
upon a bleeding episode to encourage proper homeostasis. In 2015, Adynovate (BAX 855), a
PEGlyated full length recombinant hFVIII based on Advate, was approved for both episodic and
prophylactic treatment.19 Adynovate has an extened half-life due to the addition of polyethlene
glycol on the recombinant hfVIII, and thus serving as a better therapeutic for hemophilia A.
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Hemophilia A Treatment Complications

Even with the high efficacy of these infusions, approximately 30% of the patients who
receive direct transfusion of hFVIII eventually develop inhibitory antibodies, an immune
response leading to the clearance of FVIII from circulation. This inhibitory response leaves the
patient with difficulty maintaining homeostasis due to hFVIII being cleared from circulation.
Although Immune responses have been noted with patients with mild to severe hemophilia A, it
has been noted that patients with higher quantities of genetic mutations that lead to productions
of non-endogenous FVIII often suffer from severe immune response. This is likely due to the
patient’s body not being able to recognize the FVIII as native.20
Immune tolerance induction (ITI) is a one treatment utilize to combat the inhibitory
response by eradicating inhibitors that have been developed by the body and normalizing
pharmacokinetic parameters. This is done by frequent administration of large doses of hFVIII,
over long-term to eventually abolish the immune response against recombinant hFVIII.
Immunosuppressive drugs or proteins are often accommodated in this treatment to ensure
success and effectiveness. Due to the high levels of hFVIII often required to induce an immune
tolerance, the treatment option is often extremely costly for patients; and can be physically
taxing on patients with poor venous access. In addition to the potential financial challenges this
treatment option poses, it is not successful in approximately 25% of cases. This leads to the
ongoing need for additional alternative treatment options for hemophiliacs that suffer from
extensive inhibitory responses.
To combat the anti-FVIII inhibitory response in patients, bypassing agents such as
activated prothrombin complex concentrates (PCC, also known as the factor IX complex) and
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recombinant activated factor VII replacements are utilized as primary therapies.21 Porcine FVIII
(pFVIII) is also often utilized as a treatment plan secondary to bypassing agents due to its low
cross-reactivity to anti-FVIII antibodies. Another reason for pFVIII is considered a worthy
substitute for FVIII replacement is that pFVIII more stable and more active than FVIII due to its
A2 domain being in a tighter complex within its active form.
One of the main complications of replacement therapy in hemophilia is the formation of
inhibitors neutralizing FVIII antibodies. This is due to the inhibitors rendering replacement
treatment essentially ineffective due the half of life recombinant FVIII (rFVIII), and the body
therefore concludes elimination of the recombinant protein as top priority. There have been
strategies employed to produce less immunogenic hFVIII that maintains a longer half-life in
circulation. Protein engineering has made this possible in the form of PEGylation. Addition of
polyethylene glycol polymers to the targeted proteins have been shown to increase circulation
time by masking the molecule that its attached to from the immune system and reducing
clearance by the kidneys.22 One of the recombinant hFVIII mentioned earlier, Adynovate, is a
PEGylated form of recombinant hFVIII which provides it with an extended half-life to serve as a
therapeutic. Furthermore, a recombinant factor VIII-Fc fusion protein (rFVIIIFc) has been
constructed to potentially reduce the frequency of FVIII dosing with its extended half-life.
RFVIIIFc is a recombinant fusion protein composed of recombinant FVIII and covalently bound
to the Fc domain of immunoglobulin F1 Fc region (IgG1). Studies have shown that the Fc region
of IgG1 has the potential to interact with immune cells expressing Fc receptor and thereby
affecting the immune response to rFVIII.23–25
Lastly, bispecific antibody studies have also been utilized as therapeutic treatment for
hemophiliacs. A bispecific monoclonal antibody is usually an artificial protein that combines two

18

or more antigen-recognizing elements into one construct, allowing it to simultaneously bind to
two different antigens. A recent bispecific antibody, Emicizumad (ACE910), also known in the
United States as HEMLIBRA®, has proven to be successful in Phase I clinical trials and well
tolerated by healthy subjects. Emicizumad is noted to bind, and bridge activated factor IX and
factor X, thereby acting as a factor VIII-mimetic agent.26–28 Due to its unique structure,
Emicizumab has not been subjected to recognition by FVIII inhibitors. More importantly,
Emicizumab has a much longer half-life (approximately 4-5 weeks in healthy subjects) than
recombinant FVIII. The bispecific antibody and its FVIII mimetic effects may abate both the
frequent clinical visits and emergency visits for hemophiliacs.28

FVIII and Inhibitory Antibodies: G99

Detailed knowledge of the structural interactions between FVIII and its inhibitory
antibodies are necessary to enhance and improve hemophilia A therapeutics; therefore, a
thorough understanding of immunoglobulin G (IgG) is vital. Immunoglobulins contain a heavy
chain and a light chain, which are identical to each other. In this Y-shaped monoclonal antibody
(MAB), there are two types of fragments: the constant fragment (Fc), and the antigen binding
fragment (FAB). As the name suggests, the FABs are responsible for binding to the antibody’s
target whereas the Fc region of the antibody is conserved. Each antibody contains two FABs and
they are located at the tips of the antibody’s arm (Figure 7).
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Figure 7. Schematic of antibody structure, the antibody consists of two separate FAB. Light chain
is noted to have the shorter arm, heavy chain noted on the inner (longer) arm of the “Y” shape,
complementarity determining regions (CDRs) noted in black dash lines within the antigen
binding site, and each of the FABs heavy and light chain are connected via disulfide bonds noted
in red dashes.

Due to FABs high variability, it is able to bind to its target (antigen) with exceptional specificity.
Each FAB contains two variable domains, one from the light chain and the other from the heavy
chain. Within each of these variable domains, it contains three complementarity determining
regions; and these contain variable loops that are responsible for recognizing specific regions of
the antigens known as epitopes. This is the reason why FABs can bind to its antigen with such
high specificity. The two FABs can be proteolytically cleaved from the Fc domain via proteolytic
enzyme papain (derived from papayas), allowing studies for antibody to antigen interactions by
utilizing individual FABs bound to their protein of interest.
Characterization of immune responses on FVIII has shown that a large majority of
antibodies against FVIII bind specifically to the A2 or C2 domains.29 There are two categories of
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antibodies that inhibit FVIII function: the classical antibody and the non-classical antibody.
Classical antibodies are antibodies that directly block the binding of C2 domain to von
Willebrand Factor or to phospholipid surfaces.30 On the contrary, non-classical antibodies
prevent FVIII activation by thrombin or FXa. For this research aim, only the nonclassical
monoclonal antibody (MAB) G99 was utilized for experimentation. Instead of the isolated C2
domain of FVIII, the chimeric structure of FVIII (ET3i) was utilized for this study which will be
discussed later. Structural studies have shown that the epitope face where G99 FAB binds
contains an electrostatic interaction where G99 has a negatively charged pocket that allowed the
basic Lys2227 residue in the C2 domain to bind (Figure 8).31
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Figure 8. X-ray crystal structure of the chimeric FVIII structure, ET3i bound to a non-classical
anti-C2 domain inhibitory antibody, G99 FAB. C1 and C2 share structural homology, the C
domains are noted in cyan. G99 FAB is depicted in green, bound to C2 at its basic pocket
Lys2227. (PDB ID: 7KBT. Adapted from Ronayne et al. 2021).32
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Chapter 2

Introduction to von Willebrand Disease
As discussed in chapter 1, there has been substantial characterization of FVIII and its
inhibitory antibodies. This has significantly enhanced our understanding of hemophilia A and its
therapeutic treatments. However, there is an important interaction that is still not well known;
FVIII and its circulatory partner, von Willebrand Factor (vWF) up until recently; even though it
is one of the most inherited bleeding disorders in the world.30 A recent high-resolution
cryoeletron microscopy crystal structure of FVIII:D’D3 complex was published. This 2.9Å
structure verified the important structural integrity and binding mechanism of D’D3 to FVIII.
Structural knowledge of the FVIII:D’D3 will be introduced later in this chapter.
Von Willebrand disease was first discovered in the 1920’s by a Finnish physician named
Erik von Willebrand, from whom the disease was named. Von Willebrand first characterized this
disease by studying a young girl’s case whose family had extensive hemorrhagic difficulties.33
The young girl’s family was in the Finland’s Åland islands during the study. With the island’s
smaller population, there is a higher percentage of this inherited disease, which is autosomal,
recessive. Contrary to the X-linked hemophilia A, the autosomal, recessive von Willebrand
disease can affect both male and female. In vWD, hemostasis cannot be easily achieved due to a
lack of vWF, or functionality of vWF.34–36 In severe cases of vWD, it can easily be mistaken for
hemophilia A and therefore mistreated as such. This is especially dangerous as the lack of vWF
can lead to low levels of FVIII as FVIII is not as stable without its partner and can be rapidly
degraded by proteases; thus making hemostasis even more difficult.37 Additionally, the
symptoms of von Willebrand disease is so mild that those who are affected are unaware that they
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have hemorrhagic difficulties.38 Given that most cases are mild, a large majority of von
Willebrand disease patients are treated with the on-demand administration of Desmopressin
which stimulates the release of vWF.39 In more severe cases however, IV infusions of vWF are
often required.
There are three types of von Willebrand disease, two of which are quantitative and one of
them being qualitative. Von Willebrand disease Type 1 and type 3 are quantitative disorders
where the body does not produce sufficient levels of vWF. Type 1 is where the body produces an
unusually low amount of vWF. This is the most common form of the disease, approximately
75% of cases seen are type 1 and they are usually very mild in nature.40 Type 3 vWD is the rarest
and most severe form of the three disorders where the body fails to produce any viable vWF,
thus leading to borderline non-existent levels of fVIII.41 Lastly, vWD type 2, is a qualitative
disease that affects vWF’s ability to associate properly to other proteins of interest. There are
four subcategories of type 2 vWD: 2A, 2B, 2M, and 2N.42 Each of these subcategories involve a
gene mutation that affects vWF’s ability to properly bind to its various associated partners, and
therefore affecting hemostasis. Type 2N, also known as the Normandy type, is the von
Willebrand disease of interest in this study. Type 2N is caused by the inability of vWF to
associate to FVIII and thus presenting similarly as hemophilia A and its respective levels of
FVIII in circulation.43
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Introduction to von Willebrand Factor

As mentioned previously in chapter 1, von Willebrand Factor serves as an important part
to the coagulation cascade to promote hemostasis. In the event of an injury, vWF binds to the
subendothelial collagen through its A3 domain, followed by binding to the inactive platelets via
its A1 domain to the platelet glycoprotein (GP) receptor; thereby recruiting additional platelets to
the site of injury.44 Additionally, vWF also serves the important role as FVIII’s circulatory
partner to ensure FVIII’s stability in circulation. An estimated amount of 95% of FVIII in
circulation is partnered with vWF, the partnership between the two proteins prevents proteolytic
cleavage during circulation. Furthermore, the vWF:FVIII complex prevents premature
association of FVIII to FXIa or activated platelet.45,46 The importance of the protein-protein
interaction have proven to be evident in the severity of vWD type 2N and 3; where the body
produces normal level of FVIII but often rests at hemophiliac’s level due to the body’s inability
to effectively bind to vWF.
Von Willebrand factor (vWF) is a 2,050 residue glycoprotein that is mainly produced in
endothelial cells and megakaryocytes.47,48 This protein is synthesized with 2,813 residues,
including 22 amino acid signal peptides followed by a 741 residue propeptide (D1 and D2) that
is later proteolytically cleaved.47 VWF was previously known to be synthesized with the
arrangement of D1-D2-D’-D3-A1-A2-A3-D4-B1-B2-C1-C2-CTCK (Figure 9).47–51 However,
further studies of sequence and structure of vWF indicated heightened complexity than initially
sought with complex assemblies that lack hydrophobic cores but are connected via extensive
disulfide linkages.52 Given that there are multiple domains, vWF will be briefly discussed by
their associated domains alphabetically. The three A domains are large and globular in
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comparison to the D domain. The A domains are also the only domain in vWF that lack an
abundance of cysteines in comparison to the rest of the domains. The B and C domains have also
been annotated in certain studies as six tandem von Willebrand C (vWC). The vWC-like
domains are followed by the C-terminal cysteine knot (CTCK) domain.53 Recent studies have
shown that the D domains are consists of smaller modules, also known as the vWD domain,
cysteine-8 (C8) domain, trypsin inhibitor-like (TIL) domains, and E domains.

Figure 9. VWF Schematic (adapted from Dagil et al. 2019): domain arrangement of full length
vWF. Propeptide composed of the D1 and D2 assembly followed by a furin cleavage site prior to
the D’ domain. The D’ domain is also composed of two separate domains, the TIL’ and E’
domains, highlighted in light green where FVIII binds (indicated in purple). The D’ domain is
the opening domain for mature von Willebrand factor.54
The primary FVIII binding site on vWF is located in the D’D3 domains (Figure 9).54,55
Recent studies have shown that the D’ domain is most involved and responsible for binding to
FVIII. The D’ domain is composed of two components, the trypsin-inhibitor-like domain (TIL’)
and the E’ domain (Figure 9).56 Previous studies on epitope mapping utilized anti-vWF
monoclonal antibodies along with a large percentage (approximately 72%) of missense
mutations leading to type 2N vWF are located in the TIL’ domain.57 A previous solution
structure of independent TIL’E’ published in 2014 by Shiltagh et al. provided information
regarding the D’ domain’s dynamicity and its involvement in FVIII binding (Figure 10).56 The
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authors proposed a binding mechanism in which the positively charged region in TIL’ along with
its inflexible scaffold in the E’ region forms an electrostatic attraction with the acidic region of
the A3 domain of FVIII. Furthermore, the A3 domain of FVIII has been proven to be critical for
vWF binding, which makes this proposed interaction more feasible and worth studying.56,58 As
noted, the A3 domain of FVIII is the primary binding site for the D’ region, however, studies
have shown that full length vWF also involves binding sites in the C2 domain of FVIII.59,60
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Figure 10. Solution structure of the D’ (TIL’E’) domain of vWF (PDB ID: 2MHP). The TIL’
region is labeled blue and the E’ domain is labeled red. Disulfide linkages are noted in yellow,
and the beta strands are numbered in the order they present themselves in TIL’ and E’ domains
independent primary sequences. It’s noted that 70% of beta loops reside in the TIL’ domain, and
that the five conserved cysteines in the TIL’ domain serve as its primary stabilizing force.47 TIL’
(blue) is formed of two ß sheets, ß1 and ß2 (residues 772-775 and 806-809, respectively), which
then forms a scaffold containing a long 30 residue loops, ß1- ß2 loop. The ß1- ß2 loop involves
an eight-residue gap between the second and third conserved cysteine residues (C776 and C804).
The conserved cystines in the ß1-ß2 provides the TIL’ domain with its intrinsic dynamic
character.22,56
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Crystallography of the isolated D’ domain of vWF has proven to be difficult due to its
flexibility.56 Therefore, we attempted to co-crystalize the small fragment of vWF, TIL’E’, in
complex with the chimeric structure of FVIII, ET3i. During the continuous pursuit of the
TIL’E’:ET3i complex crystal trials, a recent publication revealed a high-resolution structure of
FVIII:D’D3 complex via cryo-electron microscopy (Cryo-EM) (Figure 11). The 2.9Å structure
of the FVIII:D’D3 complex was completed with a bioengineered clinical-stage FVIII molecule
deemed BIVV001. Recombinant FVIII have proven to extend the half-life of FVIII in
circulation, though most FVIII products are constrained to an 18-19 hour ceiling imposed by
vWF-mediated clearance.55 The novel BIV001 designed and utilized in the high resolution
crystal structure consisted of a single-chain human B domain-deleted rFVIII, two IgG1 Fc
domains, D’D3 domains of vWF, and two XTEN polypeptide linkers. This bioengineered FVIII
was designed to overcome the vWF-mediated half-life ceiling. In other words, the novel
BIVV001 resulted in a stabilized rFVIII-D’D3 complex.55 The structure showed sulfated FVIIIa3 Y1680 interacting directly with the side chain of TIL’, R816, and mutations in either residue
may cause disease (Figure 12). Mutations on Y1680 may cause severe hemophilia A, and
mutations on TIL’ in vWF may cause some of the most severe forms of vWD type 2N (Figure
13). Thus, supporting the significance of proper binding between the two residues.58 Most
importantly, the complex structure further confirmed the long proposed binding hypothesis made
by Smith et al: the TIL’ domain interacts largely with the C1 and A3 domain via Van Der Waals
interactions (Figure 14, figure 15). Notably, the FVIII a3 acidic peptide region established as a
critical determinant of FVIII-vWF complex formation which inserts into a basic groove formed
at the TIL’E’ and rFVIII interface. Lastly, in contrast to previous studies and hypotheses made,
the TIL’ domain does not make any contacts with the C2 domain of FVIII.55
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Figure 11. Cartoon representation of recently published crystal structure of FVIII:D’D3 (PDB
ID: 7KWO). The C domains that observe structural homology are noted in cyan, and the A
domains are noted in different shades of blue, D’ of vWF is noted in red with direct interaction
with the acidic a3 peptide (noted in yellow) as well as the C1 domain. The D3 domain of vWF is
noted in orange;
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Figure 12. Figure of sulfated Y1680 noted in sticks (yellow), the side chain of TIL’ R816 noted
in red. The high-affinity electrostatic interaction noted in gray doted lines. Mutations noted to
either residue would result in deleterious effects and cause severe forms of hemophilia A and
vWD type 2N (adapted from Fuller et al. 2021).
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Figure 13. Mutations noted in FVIII (left) causes hemophilia A, specifically the mutations noted
in the A3 and C1 domain. Mutations noted in vWF (right) causes von Willebrand disease, with a
large majority in the D’ domain (red) which causes type 2N vWF.
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Figure 14. Electrostatic surface map of full length FVIII:vWF, colors are labeled depicting each
domain. The a3 domain of FVIII has been highlighted yellow indicating the acidic binding
pocket. TIL’E’ is noted to engulf the a3 domain with electrostatic interactions as well as the Nterminus being docked into the A3 region’s basic pocket.
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Figure 15. Figure of small pocket insertion of vWF TIL’ into the A3 domain (violet) shown in
surface rendering with its shape complementarity to the C1 domain, noted in cyan. Insertion of
vWF TIL’ (red ribbon) N-terminus S764 in a small and shallow pocket of the A3 domain is
visualized here.

Lastly, the complex structure further verified the E’ domain of vWF being the connector between
the TIL’ domain and the D3 domain; as it makes minimal contact with FVIII, and there are not
many type 2N mutations documented in this region.
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Chapter 3

TIL’E’ Mutants Designs

The solution structure of TIL’E’ as well as the recent cryo-EM structure of FVIII:vWF
have allowed a magnitude of interpretation on type 2N vWD missense mutations. The most
severe forms of type 2N vWD missense are noted in the TIL’ region that affects binding to
FVIII. In order to further understand some of the most documented missense mutations that
cause severe type 2N vWD, detailed structural understanding along with binding mechanism is
necessary. Site directed mutagenesis was employed in this present study to further understand the
binding mechanism of TIL’E’ to ET3i in addition to the recent FVIII:vWF structure. Up until the
recent structure, the proposed binding mechanism has been the electrostatics interaction with the
A3 domain of ET3i.11,56 The most recent cryo-EM structure confirms the previous studies of
FVIII/TIL’E’ binding mechanism and its previously proposed docking system.55 The primary
binding region was noted in the TIL’ domain of vWF, and mutations that cause changes in
electrophobicity or hydrophobicity may affect binding and/or structural integrity and thereby
affect its functionality. Therefore, the mutants selected have been previously documented to
cause the omst severe forms of type 2N vWD. Three out of the four mutants were selected in the
TIL’ domain and one in the E’ domain for further analyses (Table 1).
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TIL’

E’

Mutation Position
R816Q ß3

Hypothesis
Loss of conserved positive charge in the
presumed A3 binding region

E787K

Introduces positive charge in region of negative
charge. Significantly decreases binding

ß1-ß2 Loop

R782W ß1-ß2 Loop

Loss of positive charge, change of polar to
hydrophobic.

R854Q

Loss of positive charge in FVIII anchor region

ß4-ß5 loop

Table 1. List of TIL’E’ mutations, position of the mutation in the TIL’E’ structure, and
hypotheses of effects on binding to ET3i.

The mutations selected in the TIL’ domain include R816Q, E787K, and R782W; and
R854Q in the E’ domain. No cysteines involved in any disulfide bonds were selected in this
study as previous studies have shown multimerization, poor secretion, and reduced FVIII binding
when cystine mutations were involved. This is due to TILL’E’ lacking a hydrophobic core, and
the disulfide bonds involved in the structure serves as its primary stabilizing force. In other
words, proper disulfide bond formation is necessary to the folding as well as function of vWF.7
R816Q is located in the TIL’ domain of vWF, the mutation from arginine to glutamine creates a
loss of conserved positive charged in the A3 binding region of FVIII (Figure 16). Given the
proposed electrostatic interaction, the hypothesis of this mutant results in a decrease in binding
affinity to FVIII. E787K and R782W are considered to be some of the more severe forms of type
2N phenotypes. The E787k mutation creates a positive charge in the binding protrusion, and thus
likely would generate a significant disruption to binding to FVIII from a structural perspective.
Furthermore, E787 along with R782 are in close proximity of the ß1-ß2 Loop where it is highly
flexible, meaning that a missense may potentially involve a conformational change with
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deleterious effect that significantly reduces binding to FVIII (Figure 17). R782W involves a
mutation to tryptophan. This causes a change from the part hydrophobic and positively charged
residue, arginine, to a neutral charge hydrophobic residue, tryptophan. The loss of the positively
charge along with an increase in hydrophobicity may cause structural perturbation and
significantly decreases binding to the putative A3 binding pocket (Figure 18). Lastly, the only
mutation selected in the rigid E’ domain, R854 with a mutation to a glutamine introduces a loss
of positive charge (Figure 19). Though the E’ domain does not make significant contact with the
binding pocket of the C1 domain of FVIII, the mutation may affect how TIL’ is connected to the
E’ domain of D’. The mutation may cause misfolding of the protein and therefore may poorly
anchor itself to FVIII. The designed mutants were then compared to the binding of wild type
(WT) TIL’E’.

Figure 16. Stick representation of arginine mutation to glutamine at R816 (red). The mutation
from an arginine to a glutamine introduces a loss of positive charge to the binding region of
FVIII. This mutation has been documented to be one of the most severe forms of vWD type 2N
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missense, and it’s proposed to significantly reduce binding to the acidic region of a3, and
therefore affects the high-affinity interaction with sulfated tyrosine at residue 1680.

Figure 17. Stick representation of glutamic acid 787 mutation to positively charged Lysine (red).
This mutation introduces an overall positive charge in a region within TIL’ that is negatively
charged and is hypothesized to affect proper disulfide formation of TIL’ and thereby affecting its
binding capabilities to FVIII. Overall charge of the residue is noted to be positive instead of the
negatively charged wild type glutamic acid.
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Figure 18. Positively charged Arginine 782 (red) mutation into hydrophobic and neutral
tryptophan. This mutation may affect the proper folding of TIL’ and therefore affecting its
functionality.

Figure 19. R854 located in the E’ region has been reported to serve as an anchor into C1 domain
of FVIII. Loss of positive charge from an arginine to a glutamine would affect its ability serve as
a proper anchor to FVIII.
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Research Aim

The goals of this present study include successful expression and purification of all
mutants designed along with the wild type protein. Following successful purification of TIL’E’
and its corresponding mutants, wild type TIL’E’ in complex with our chimeric FVIII, Et3i, were
formed for X-Ray crystallography attempts via hanging-drop vapor diffusion. Affinity pull-down
assays were employed to assess binding between mutants and ET3i. Biolayer interferometry
(BLI) was also employed to further study binding affinities to FVIII of all mutants in comparison
to wild type. The aim of the BLI is to acquire quantitative data to further support and understand
binding mechanism via kon, koff, and KD data.
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Chapter 4

Materials and Methods

Wild type TIL’E’ and each of the mutants described in chapter 3 were transformed,
expressed, purified, proteolytically cleaved, and stored for future assays and crystallography
trials. Binding assays conducted include biolayer interferometry, pull down assays, and
sedimentation assays. Each portion of methods will be discussed in its corresponding section.

DNA Plasmid Transformation of TIL’E’ and Mutants

The pET32b(+) vector encoding the TIL’E’ domain of vWF used in this present study
was obtained from the Hansen Lab located in the University College London. This plasmid also
encoded the thioredoxin (TRX) fusion protein tag along with the N-terminal internal (His)6-tag.
The protein and the (His)6-tag are separated by a 31-residue linker protein and tobacco etch virus
(TEV) protease cleavage site (Figure 20). Additionally, all mutants designed as mentioned in
chapter 3 have adopted this schematic with single point mutations in its sequence. The TIL’E’
mutant sequences were constructed utilizing the pET32b(+) vector with an ampicillin resistance
site. The TIL’E’ mutant plasmids were acquired from GenScript in lyophilized form and were
transformed into chemically competent cell lines.
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Figure 20. Schematic of expression product from TIL’E’ plasmid obtained from Hansen Lab
(University of College London). Construct depicts arrangement of the TIL’E’-TRX fusion
protein utilized in this project.

Bioengineered chemically competent SHuffle® T7 B E. coli cells purchased from New
England Biolabs (NEB) Inc. SHuffle® cell line was transformed with the pET32b(+) plasmids
encoding the TIL’E’ mutants. The cells were transformed following the optimized protocol
provided by NEB, resulting in single colonies grown on LB Agar plates. Approximately 100ng
of selected TIL’E’ or TIL’E’ mutant DNA were utilized and incubated with the T7 competent E.
coli cells for 30 minutes on ice. The cells were then heat shocked at exactly 42oC for 30 seconds,
followed by a five-minute incubation on ice. One milliliter of room temperature Super Optimal
Broth with Catabolite repression (SOC) medium was added, and the mixture was shaken at
250rpm for 60 minutes at 30oC. The cells were then spread onto LB agar ampicillin50 plates via
sterile technique and incubated overnight at 30oC. The overnight plate yielded multiple colonies
of cells, and a single colony was harvested and grown for cell stock as well as large scale growth
and expression.

Large Scale Growth and Expression

Ten milliliters of Luiria Bertani (LB) broth containing 10% w/v Bactotryptone, 5% w/v
yeast extract, and 10% w/v sodium chloride were utilized as starter culture. These 10ml LB
broths were prepared beforehand in bulk. The room temperature 10ml LB broths are then
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inoculated with the selected colonies from the overnight plate along with amplicillin50 (Amp)
and are allowed to grow overnight at 200rpm and 30oC. The starter cultures were then utilized to
inoculate 1L LB and Amp broths for large scale growth. The 1LB/amp broth are grown at 30oC
until an OD600 reading of at least 0.6 AU was reached, then the broth was induced with 400μl of
1M Isopropyl β-D-1-thiogalactopyranoside (IPTG). The temperature was then lowered to 15oC
for overnight expression.

Affinity Chromatography Purification

The cells were harvested within 16-20 hours of expression at 15oC with the F12-6x500
LEX rotor from Thermo Scientific for 10 minutes at 6371 g-force and 4oC. The cell pellet was
collected and resuspended in lysis buffer containing 20mM Tris-HCl (pH 7.5), 500mM NaCl,
and 10mM imidazole along with 350μl of 1M phenylmethylsulfonyl fluoride (PMSF), and 700μl
of 1M Lysozyme. This was followed by 35 minutes of incubation time on ice with gentle
intermittent mixing of the resuspension. The resuspended cells were lysed via sonification using
a Branson Sonifier 450 probe with a power output of five and duty cycle of 50% for one minute.
In the event a larger cell pallet, a 30 second recovery time was applied between sonification. Cell
debris was removed by a secondary high-speed centrifuge spin. The lysed cells were centrifuged
at 17,000rpm in an F20-12x50 LEX Thermo Scientific rotor for 45 minutes at 4oC. The highspeed supernatant was filtered manually via a syringe with a 5μm filter. In a larger scale (6L12L) growth, multiple 5μm filters may be required. In the event of clogging, a secondary 5μm
filter was utilized for filtration prior to purification.

43

Immobilized metal affinity chromatography (IMAC) was employed for TIL’E’ and
TIL’E’ mutant purification. 1ml of settled Ni-NTA Agarose resin obtained from Qiagen was
used for 2L of E. coli cell growth. The resin is initially equilibrated into lysis buffer as
mentioned above. The lysate was then flowed through it with a 15-minute incubation time along
with intermittent agitation of the resin. The column was then washed twice with 20 column
columns (CV) of wash buffers with increasing concentrations of imidazole, first 20mM followed
by 40mM. The protein was finally eluted with 30 CV of elution buffer containing 20mM TrisHCl (pH 7.5), 500mM NaCl, and 200mM imidazole. A gel sample was obtained for each of the
wash steps and the elution step for sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) verification. The fraction containing the most protein was then dialyzed in a 15
kDa molecular weight cut-off dialysis tubing by Spectrum Laboratories, Inc. overnight at 4oC in
dialysis buffer (20mM HEPES, 150mM NaCl, and 1% (v/v) glycerol).

TEV Cleavage

Tobacco etch virus (TEV) protease was utilized to cleave the TRX-(His)6-tag-linker
fragment from TIL’E’. A ratio of 1 OD280 TEV to 10 OD280 TIL’E’ was utilized for this cleavage
reaction. Samples containing the fusion (His)6-tagged TIL’E’ and TEV were incubated at room
temperature for three hours, then was moved to 4oC overnight for the completion of the cleavage
reaction. The following day, a second nickel column was set up to capture the cleaved protein.
Similar to the initial nickel column, the resin was initially equilibrated with lysis buffer followed
by equilibration with the (His)6-tagged TIL’E’ with TEV to encourage binding of the (His)6 trap
with the resin. The resin was then washed with two separate 20 CV washes of 20mM and 40mM
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imidazole, followed by the elution buffer. Once again, gel samples were obtained at each step for
SDS-PAGE verification and efficacy of the TEV cleavage reaction. The very initial fraction
(flow-through) was collected, concentrated, and buffer exchanged into HBS (storage buffer) via
Amicon Ultra-15 Centrifugal filters (Ultracell 10K Millipore membrane). In the event where the
volume is too much for buffer exchange, secondary dialysis would take place under the same
conditions as the initial dialysis noted previously.

Size Exclusion Chromatography

Size exclusion chromatography (SEC) served as the final purification step for TIL’E’.
TIL’E’ was injected to a HiLoadTM 16/60 Superdex 75 (S75) preparatory grade size exclusion
chromatography column by GE Healthcare. The column was washed with nanopure water prior
to equilibration with HBS (storage buffer). The peaks on the chromatogram were further
collected for SDS-PAGE analysis and confirmation.

Affinity Pull-Down Assays (Ni-NTA Agarose Resin)

Ni-NTA Agarose Resin by Qiagen was utilized for initial binding assays. TRX-(His)6tagged TIL’E’ and tagged TIL’E’ mutants were incubated in equilibrated 100µl of Ni-NTA resin
at room temperature for 15 minutes to encourage binding. Following incubation, tagged TIL’E’
was then transferred to a Costar Spin-X® centrifuge tube filters, 0.22µm pore CA, then was
washed twice with 10 CVs of HBS (storage buffer) with intervals of 800 x g spins. Following the
washes, an equimolar ratio of ET 3i was added to the resin, and the sample was incubated at
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room temperature for 5 minutes to encourage binding. The resin was then washed once with
HBS (storage buffer), then eluted with elution buffer. Gel samples were collected at each flow
through, wash, and elution step for further analyses via SDS-PAGE.

Affinity Pull-Down Assays (TALON Magnetic Beads)

TALON Magnetic beads by TaKaRa was employed for affinity pull-down assays, and the
magnetic beads were first removed out of its ethanol storage into nanopure, followed by
equilibration into HBS (or whichever the protein was dialyzed and stored into). Following
similar protocol as an IMAC, a 1:1 ratio of TIL’E’ (TIL’E’ mutants):ET3i was utilized for the
binding assay. Approximately 15µg-30µg of TIL’E’ was used and only 15µg of ET3i was used.
Upon equilibration of the magnetic beads TALON resin, TIL’E’ was incubated with ET3i
without any disturbance of the resin for 15 minutes. The magnetic bead resin was then lifted
aside of the Eppendorf tube via a strong magnet, and the flow through was extracted. The resin
was washed twice with low imidazole content followed by a high imidazole elution buffer. Each
column flow through, wash, and elution were extracted similarly with a strong magnet. Each
column fraction collected was analyzed via SDS-PAGE.

Liposome binding: Sedimentation Assays

Anionic dioleoyl phosphatidylserine (DOPS) and zwitterionic dioleoyl
phosphatidylcholine (DOPC) were utilized in sedimentation assays mimicking platelet binding.
A 80:20 DOPS:DOPC ratio was utilized in each of the sedimentation assays, and the liposomes
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were prepared in bulk and the stock liposomes are stored in -20oC in argon gas. Six separate
Beckman Coulter tubes (PC TK Wall 8x23mm) were made and they are labeled as ET3i:PC,
ET3i:PSPC, TIL’E’:PC, TIL’E’:PSPC, ET3i:TIL’E’:PC, and ET3i:TIL’E’:PSPC. Each tube
consists of their corresponding components with a final volume of 300µl (125µl of DOPC, 125µl
of DOPS (80:20), 1:1 equimolar ratio of TIL’E’ and ET3i, brought to final volume with nano
pure water). The mixture was para-filmed and incubated at room temperature for one hour prior
to high-speed centrifugation. The Beckman tubes were then spun at 16000 rpm for 45 minutes
with Sorvall MX 150 Micro-ultracentrifuge by Thermo Scientific. The supernatant from each
tube was decanted and cold acetone (-20oC) was added for acetone precipitation, the supernatant
samples were incubated overnight in acetone at -20oC. Each of the pellets (both visible and
poorly visualized) were resuspended and agitated in 4x loading dye and stored in -20oC in
preparation for SDS-PAGE analyses. The incubated supernatant tubes were then spun at 16000 x
g for 15 minutes the following day. The supernatant of this centrifugation was decanted, and a
10-minute recovery time was allowed for excess acetone to evaporate. Loading dye was added
and the sample was agitated on Vortex 2.0 for resuspension in preparation for SDS-PAGE
analyses.

Biolayer Interferometry

Biolayer interferometry (BLI) was selected as the quantitative evaluation of binding
between ET3i, wild type TIL’E’ and TIL’E’ mutants. The bioengineered chimeric structure of
FVIII, ET3i was obtained from our collaborators, Dr. Christopher Doering and Dr. Gabriela
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Denning. BLI was accomplished with Pall ForteBio® BLITz instrument along with the BLITz
Pro software. Anti-hC2 monoclonal antibody (MAB) G99, prepared by previous lab members,
was complexed with ET3i. This complex was incubated on ice for at least 15 minutes to
encourage binding to each other. Upon initiation of the binding assay, a blank was taken where
the anti-mouse tip (AMC) is soaked in HBS. Anti-C2 MAB G99:ET3i was then bound to AMC
tips during the loading step, followed by another blank in which the buffer soaks away excess
complex that did not bind to the tip. TIL’E’ and each TIL'E' mutant was then associated to the tip
followed by a dissociation step. The data set was then extracted from the Blitz program and
processed initially in excel to ensure that the background has been subtracted off. The processed
data were then further analyzed on GraphPad Prism 8.0 where a nonlinear regression curve was
applied to the binding data. kon, koff, and KD values were obtained via GraphPad Prism.

X-Ray Crystallography

Hanging drop vapor diffusion was employed to crystalize the ET3i:TIL’E’ complex.
Suitable conditions were acquired via large scale screens through Hauptman-Woodward Medical
Research Institute; a select few conditions were further pursued. A total of 400µl were pipetted
into each of the 24 well plates. Each well was manually greased for proper sealing upon placing
of the glass slide. One microliter of the protein complex (ET3i:TIL’E’) and 1µl of the well
condition was pipetted onto the glass slide. The glass slide is then momentarily placed on top and
over its corresponding well condition, this is repeated for all 24 wells. The crystal trays were left
undisturbed for at least 24 hours to encourage vapor diffusion. Each tray was evaluated under
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microscope to check for crystal formation. Multiple trays were made with differing buffer
concentrations, pH levels, salt levels, precipitants, and polyethylene glycol (PEG) concentrations
which will be discussed in the results and discussion section.
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Chapter 5

Results and Discussion

Preparation of pure Wild Type TIL’E’ and TIL’E’ Mutants

Wild type TIL’E’ and its mutants were expressed and purified for further studies as well
as crystal trials. Bacterial expression was employed in this study, TIL’E’ and TIL’E’ mutant
plasmids were individually transformed into the New England Biolabs (NEB) bioengineered
SHuffle E. coli cell line to aid in proper disulfide bond formation. To further encourage proper
folding of disulfide bonds within D’, the plasmid was designed to contain a N-terminal
thioredoxin (TRX) tag (Figure 20).
Upon successful protein expression and harvest, a three-step affinity chromatography
with Ni-NTA Agarose was employed to ensure sufficient protein purity. The first Ni-NTA (1st
Nickel column) was utilized to separate a large majority of impurities from TIL’E’ post protein
expression. The column was washed with two low imidazole-containing buffers with a high
imidazole elution. Upon collection of each of the gravity flow columns, the purity of the
fractions was analyzed via SDS-PAGE (Figure 21). As seen in the initial nickel column, the
tagged TIL’E’ fusion protein migrates near 27kD. Some impurities are seen in the higher
molecular weight region.
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Figure 21. SDS-PAGE analysis and verification of TIL’E’ protein purity following 1st nickel
column. Lanes: 1. Molecular weight protein ladder; 2. Molecular weight protein ladder (due to
lane leakage); 3. Filtered lysate flow through; 4. Column wash; 5. Elution fraction.

Following the initial nickel column, the fraction with the highest amount of protein was dialyzed
out of imidazole and into the HBS buffer. A 2nd Ni-NTA column was employed to remove the
TRX and (His)6-tag-linker fragment via tobacco etch virus (TEV). All components along with
tagged TIL’E’ was collected in the 2nd nickel column (Figure 22). It can be visualized that there
is some tagged TIL’E’ remaining near 27 kD, along with TRX protein near 17kD and cleaved
TIL’E’ at 11kD. There is one contaminating band noted near 60 kD, and size exclusion
chromatography was employed to purify TIL’E’ further. SDS-PAGE verified pure and cleaved
TIL’E’ post SEC (Figure 23 and figure 24).
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Figure 22. SDS-PAGE analysis post TEV cleavage of TIL’E’. Undigested (incomplete TEV
digestion) Tagged wild type TIL’E’ eluting at 27kDa, thioredoxin upon digestion eluting at
17kDa, followed by cleaved TIL’E’ at 11kDa.

lanes 4-10

Figure 23. SEC Chromatogram for cleaved TIL’E elution fractions 4-10, as seen on SDS-PAGE
verification in figure 24.
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Figure 24. SDS-PAGE analysis post size exclusion chromatography (SEC). A. Elution profile of
TIL’E’ with highest peak being collectable fractions. B. Lanes: 1. Molecular weight protein
ladder; Lanes 2-3: incomplete digestion of tagged TIL’E’; Lanes 4-10: Pure cleaved TIL’E’
collectable fractions.

R816Q, R782W, E787K, and R54Q (TIL’E’ Mutants) Purification

As mentioned previously, each of the mutants were designed adopting the same sequence
as wild type TIL’E’: TRX fusion protein-(His)6-tag-linker. Each of the mutants contain a point
mutation in its corresponding amino acid sequence. The same purification and cleavage method,
immobilized metal affinity chromatography (IMAC) and TEV cleavage, respectively. SDSPAGE analyses indicated relatively pure TIL’E’ mutants. There were certain mutants that
required secondary IMAC purification for contaminant removal, SDS-PAGE verified post
purification yielded pure mutants (Figure 25-figure 28).
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Figure 25. SDS-PAGE purification of E787 and R854Q. Lanes: 1. Molecular weight protein
ladder; 2. E787K Initial lysate flow through; 3. E787K Wash column; 4. E787K Elution column;
5. Initial R854Q lysate flow through; 6. R854Q wash column; 7. R854Q elution column.
1

2

Figure 26. SDS-PAGE verification of E787K secondary IMAC. Lanes: 1. Molecular weight
protein ladder; 2. Tagged E787K initial elution fraction (buffer exchanged into HBS); 3. E787K
wash; 4. E787K elution fraction.
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Figure 27. SDS-PAGE verification of R854Q secondary IMAC purification. Lanes: 1.
Molecular weight protein ladder; 2. Intentional space; 3.R854Q lysate flow through; 4.
Intentional space; 5. R854Q wash #1 (10mM Imidazole); 6. Intentional space; 7. R854Q wash #2
(40mM imidazole); 8. Intentional space; 9. Tagged R854Q elution fraction.
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Figure 28. SDS-PAGE verification of tagged R782W and R816Q. Lanes: 1. Molecular weight
protein ladder; 2. Initial R782W lysate flow through; 3. R782W wash column; 4. R782W elution
column; 5. Intentional space; 6. Initial R816Q lysate flow through; 7. R816Q wash column; 8.
R816Q elution column.

Biolayer interferometry Binding Kinetics

Previous studies have hypothesized electrostatic interaction between TIL’E’ and FVIII in
the a3 domain of FVIII and the TIL’ domain of D’. As mentioned previously, during the
composition of this project, a high-resolution complex cryo-EM crystal structure confirmed the
Van Der Waals interaction the D’ domain of vWF has on the a3 and A3 domains of FVIII. To
further study the interaction between FVIII and TIL’E’ in a quantitative manner, biolayer
interferometry was employed. Serial dilutions of TIL’E’ with HBS was made (2x dilution),
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triplicate experiments were conducted for wild type along with each of the mutants to gather a
series of data sets for analyses. To successfully bind TIL’E’ to FVIII, an Anti-Mouse IgG Fc
capture (AMC) was utilized with monoclonal antibody (MAB) of choice, G99, in complex with
ET3i. G99 has a reported binding affinity to FVIII of 15.5nM.53 A 1:1 ration was employed for
the G99:ET3i complex (Figure 29). The mixture was incubated for at least 15 minute to
encourage binding. Following the protocol provided by Blitz, total of five sets of triplicate data
was acquired. Each of these raw data sets were processed through excel to normalize the
background data. Following background normalization, the data sets were processed once again
with GraphPad Prism 8.0 for kon, koff, and KD quantification (Figure 30 and Table 2).
Quantification data indicated decrease in binding with decreasing concentrations of TIL’E’ in
complex with G99:ET3i, which was expected.
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Figure 29. Schematic of the G99:ET3i complex utilized in BLI experiments. G99 (orange)
binding to the C2 domain of FVIII (cyan).
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Figure 30. Non-linear regression curves for WT TIL’E’ along with each of its mutants. The
graph presented is an averaged data set from triplicate experimentations with normalization
(subtraction of background). A. G99:ETi3i:WT TIL’E’ with an initial TIL’E’ concentration of
137µM. B. G99:ET3i:R816Q with an initial R816Q concentration of 262.6µM. C.
G99:ET3i:R854Q with an initial R884Q concentration of 90.7µM. D. G99:ET3i:E787K with an
initial concentration of E787K of 66.6µM. E. G99:ET3i:R782W with an initial concentration of
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R782W of 274.1µM. Both WT TIL’E’ along with each of the mutants demonstrated relatively
more stable binding at its stock (highest) concentration with a higher phase shift.

Mutants
WT TIL'E' (G99)
R816Q
R854Q
R782W
E787K

kon

koff
234983
243936
1473202
284831
541763

KD
0.2875 122nM
539nM
0.1315
160nM
0.2359
0.1089 380nM
0.1295 240nM

R Squared
0.9551
0.9879
0.9352
0.9576
0.9891

Literature
Value
26nM +/- 2nM
N/A
N/A
N/A
N/A

Table 2. Quantitative data (kon for association, koff for dissociation, and the dissociation constant,
KD) for WT TIL’E’ as well as each of the mutants.

The G99:ET3i:WT TIL’E’ complex bound with a dissociate constant (KD) of 122nM in
this study, for comparison and consistency purposes, the TIL’E’ mutants will be compared to the
obtained WT TIL’E’ data at 122nM. It has been noted that the TIL’ domain missense causes the
most severe form of type 2N vWD, specifically the R816Q mutation. BLI results showed the
weakest binding affinity (KD) to FVIII which is consistent with the hypothesis. The loss of the
positive charge in the primary negatively charged a3 binding region would cause significant
deleterious effects. The significance of R816 electrostatic interaction with FVIII was further
confirmed by the cryo-EM structure; BLI data was consistent with the complex structure. E787K
and R782W both were hypothesized to affect binding due to potential conformational change of
the TIL’ domain secondary to changes in charges. BLI data confirmed the decrease in binding to
FVIII with 240nM and 380nM, respectively. R782W additionally introduced a more
hydrophobic residue, and the increase in hydrophobicity affected its ability to bind to FVIII in
comparison to E787K with a 240nM (KD), which is consistent with the hypothesis. Finally,
results indicated R854Q had the least amount of effect on binding with the highest binding

60

affinity out of all the mutants, 160nM. R854Q was hypothesized to only have minimal effect as
R854 does not make significant contact with FVIII, and the BLI results were found to be
consistent with the cryo-EM structure. All of the mutants, including WT TIL’E’, associates
quickly on the AMC tip, and dissociates at an incredibly fast rate as well (Figure 31). There were
clear phase shifts observed, and a large dissociation phase shift as well (Appendix A Figure 1-5).

Figure 31. Figure of G99:ET3i complex noted in cyan overlay with the cryo-EM structure of
FVIII:vWF complex noted in pale blue. Binding of TIL’E’ to the a3 acidic peptide noted in red
and yellow, respectively. This is a complex representation utilized in the BLI. Structurally, the
G99:ET3i complex binds to the AMC tip, followed by D’ of vWF’s association. There are no
noted binding overlaps, each complex has a different binding motif; with G99 binding at C2, and
TIL’E’ binding to the a3 and C1 domain of FVIII. (WT TIL’E’ PDB ID: 2MHP)
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Affinity Pull-Down Assay

Qualitative analyses of the TIL’E’ mutants against ET3i were conducted via affinity pull
down assays with TALON magnetic beads. The TIL’E’:ET3i complex served as a control in the
affinity pull-down assay. The complex was accomplished by binding TIL’E’ to ET3i, to ensure
that the tagged proteins and magnetic beads were viable for the assay. The initial TIL’E’:ET3i
complex was incubated at a 1:1.25 ratio at room temperature prior to the initiation of the assay.
Controls showed successful interaction between TIL’E and ET3i, as two bands were visualized
in the elution fraction (Figure 24). It was quickly noted that the TIL’E’ mutants are not
remaining bound to the resin during wash steps. This is evident when comparing the mutants to
wild type TIL’E’ and D’D3 bound to ET3i (Figure 31). Tagged mutants were bound to the resin,
followed by the addition ET3i. Upon wash steps, some protein was lost and subsequently, some
of the already limited amounts of ET3i may have also eluted off the column during wash steps.
Upon elution, only the bound mutants were visualized on the gel, and no ET3i were detected.
Multiple trials have indicated that ET3i has become too dilute to be analyzed on SDS-PAGE.
Higher concentrations of ET3i were utilized for this affinity pull-down without significant
improvement. The qualitative studies are consistent with the data obtained from the BLI. As
quantified, the mutants associate quickly onto the AMC tip with a high kon value, remained
bound to ET3i, followed by an incredibly fast off rate (koff). This is likely the explanation to the
difficulty seen in this binding study.
In figure 32, the most severe type 2N missense (R816Q) along with the mutant that was
hypothesized to cause structural perturbation the TIL’ domain, R782W, were selected for
analysis. In lanes 1-4 are the flow through and wash steps of R816Q:ET3i, and ET3i did indeed
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slowly dissociate from R816Q which was bound to the resin. Lane 5 demonstrated an extremely
faint line for ET3i (nearly invisible), but R816Q did elute from the column. The lack of ET3i in
the complex indicated that ET3i quickly dissociated or was unable to remain bound to R816Q
throughout the wash steps. This is consistent with quantitative findings of the weakest
dissociation constant (KD) of 539nM when compared to other mutants and wild type (Table 2).
Lanes 6 and 7 represent the R782W:ET3i complex, flow through and wash step, respectively.
Lane 8 demonstrated the R782W elution fraction, which showed that R782W successfully eluted
off the column without the presence of ET3i, as demonstrated by the lack of the ET3i band near
100kDa (Figure 32). The qualitative finding is again consistent with the BLI data of the second
weakest binding of 380nM (Table 2). The absence of ET3i on the SDS-PAGE verification has
proven to be consistent with the low KD and quick dissociation rates indicated in the BLI binding
kinetics study.
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Figure 32. SDS-PAGE verification of protein-protein interaction between WT TIL’E’ and ET3i.
Lanes: 1. Molecular weight ladder; 2. Intended space; 3. Initial nickel column WT TIL’E’ flow
through; 4. Intended space; 5. Initial nickel column WT TIL’E’ wash fraction; 6. Intended space;
7. WT TIL’E’:ET3i wash; 8. intended space; 9. WT TIL’E’:ET3i elution fraction.
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Figure 33. SDS-PAGE verification of R816Q and R782W bound to ET3i. Lanes: 1. Molecular
weight protein ladder; 2. R816Q:ET3i flow through; 3. R816:ET3i wash; 4. R816Q:ET3i wash
#2; 5. R816Q:ET3i Elution; 6. R782W:ET3i flow through; 7. R782W:ET3i wash; 8.
R782W:ET3i elution. SDS-PAGE indicated that tagged TIL’E’ and TIL’E’ mutants could be
visualized but not ET3i upon elution.

X-Ray Crystallography

X-ray crystal trials were employed to further study vWF D’s structural integrity and its
interaction with FVIII. TIL’E’:ET3i complexes were complexed for crystallographic trials.
Multiple hits were identified from previous lab work sent and done by Hauptman-Woodward
Medical Research Institute. The 24-well via hanging drop vapor diffusion crystal trays were set
up to further pursue the conditions that contained crystals (Table 3). Initial crystal morphology
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was observed to be flat and diamond-like in the wells that contained crystal formation, instead of
a traditional three-dimensional crystal morphology. In addition, some of the initial crystals that
demonstrated a three-dimensional morphology carried multiple mesh-like layers instead of a
thick single-layer appearance. However, there were a few wells that contained full-bodied threedimensional crystals that were collected for data gathering (Figure 33).

Screen

Buffer

Salts/(other components)

pH

0.1M TAPS

Ammonium Sulfate

0.1M TAPS

Ammonium Phosphate

0.1M BTP

Lithium Bromide

0.1M TAPS

Sodium Chloride
Sodium Chloride, Al's
Oil

0.1M TAPS

PEG

Precipitants
PEG 12K
12%
PEG 20K
12%
PEG 20K
12%
PEG 1K
40%
PEG 1K
40%

0.1M TAPS (pH 9)

Ammonium Phosphate

PEG 20K

0.1M BTP (pH 7.5)

Ammonium Sulfate

PEG 4K

0.1M TAPS (pH 9)
0.1M HEPES (pH
7.4)

Sodium Chloride

PEG 1K

Sodium Chloride

PEG 4K

0.1M BTP (pH 6.5)

Potassium Bromide

PEG 20K

0.1M Tris (pH 7.5)

Lithium Bromide

PEG 20K

Manufacturer
Hampton
Research
Hampton
Research
Hampton
Research
Hampton
Research
Hampton
Research
Hampton
Research
Hampton
Research
Hampton
Research
Hampton
Research
Hampton
Research
Hampton
Research

Table 3. crystal trials and well conditions of TIL’E:ET3i complex. The 24 well trays usually
consists of two varying components, the x-axis of the tray as well as the Y axis of the tray, while
the rest of the components were kept constant (i.e. PEG screen is varying concentrations of PEG
on the x-axis, whilst pH screen is varying the pH along the y-axis). All buffers were made from a
stock concentration of 1M, salts and other components were diluted from various stock
concentrations.
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Figure 34. Images of crystals obtained in screens of TIL’E:FVIII complex. Crystal formation
observed to be single layered, three dimensional, and diamond-like in appearance.

The crystals in figure 33 were selected, looped, cryo-protected, and screened remotely at
THE Advanced Light Source (ALS) at Lawrence Berkeley National Labs, for potential
diffraction. The looped crystals were cryoprotected in their growing condition, and promptly
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frozen upon extraction. While we were able to grow crystals of ET3i in the presence of vWF D’,
there was no discernible electron density for TIL’E’ in complex with ET3i. However, improved
crystallographic conditions were obtained in which there were observed crystal growth, which
led to an improved resolution of ET3i.
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Chapter 6
Conclusion and Future Work

The importance of FVIII’s interaction with other proteins and its circulatory partner is
demonstrated by the different types of bleeding disorders through its absence or mutations, i.e.,
hemophilia. Similarly, vWF’s interaction with FVIII has been proven to be significant, as
mutations may substantially affect their interaction and thus causing von Willebrand Disease.
Both hemophilia A and von Willebrand Disease type 2N presents an infinite number of
complications, clinical treatments, emergency treatments, and costly financial burdens for its
patients. Therefore, structural understanding of FVIII and its circulatory partner, vWF, is crucial
to further understand the formation of these bleeding disorder. Improved understanding of these
two large glycoproteins is necessary to improve and enhance therapeutic treatments and patient
care.
New publications in the recent years have made significant strides towards structural
knowledge between FVIII, isolated domains of FVIII, vWF, D’, and D’D3 domains of FVIII. A
negative-stain electron microscopy and hydrogen-deuterium mass spectroscopy (HDX-MS)
studies with D’D3 was previously conducted.53 The findings Chiu et al. substantiate those of Yee
et al. where C1 was established as the major vWF binding site.57,58 With the most recent
publication of the high-resolution structure paved way for a better understanding for hemophilia
A as well as von Willebrand Diseases. This 2.9Å structure determined the binding mechanism of
how FVIII’s circulatory partner, vWF, interacts with it. As discussed earlier, vWF D’ domain has
been proposed to be the domain that is highly involved in the binding to FVIII. Fuller et al. were
able to confirm this interaction from their complex structure.47 Furthermore, severe hemophilia A
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and type 2N von Willebrand disease mutants were identified and discussed structurally. Fuller et
al. confirmed the significant electrostatic interaction between R816 and sulfated Y1680 in the C1
domain of FVIII (Figure 34).55

Figure 35. sulfated Tyr1680 interacting with the TIL’ domain R816 residue. The electrostatic
interactions are noted in gray dotted lines and constitutes as stabilizing force for FVIII and vWF.

Contradictory to recent publication of interaction of vWF and C2 domain, the cryo-EM structure
indicated that D’ does not involve the C2 domain when docked onto FVIII. Instead, D’ makes
the most significant amount of contact with the a3 and C1 domain of FVIII, and the D3 domain
of vWF contacts C2 domain of FVIII (Figure 27).52 The binding studies conducted in the Spiegel
Lab were evaluated and consistent with the most recent structure. The rapid association and
dissociation of all TIL’E’ mutants indicated certain deleterious effects. Quantitatively, changes
in binding that are measured 10-fold or greater usually indicates a confirmed binding
disturbance. However, the mutants’ disruption in binding to FVIII were only measured to be
five-fold less than wild type TIL’E’ (Table 2). Thus, it may be concluded that even a small
structural change or a change in electrostatic charges (structural perturbation) is significant
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enough to affect vWF’s ability to bind to FVIII. In other words, the stability of FVIII:vWF
binding may be easily disturbed, as evaluated through the BLI. Though the TIL’E’Mutants:FVIII complexes were unseen in structure (via crystallography), the binding capabilities
were quantitatively evaluated via BLI. The instabilities in binding observed in the studies that
were conducted in the research lab allowed further hypotheses and trajectories of research.
All cumulative efforts on the structure of FVIII allowed Fuller’s group to uncover the
most recent high-resolution structure. The cryo-EM structure verified that neither the C1 domain
alone nor the acidic peptide region (a3) alone were sufficient to establish stable complexes with
the vWF domains. The newly published FVIII:D’D3 structure created exciting opportunities for
the future of the blood community, as it serves as a foundation for all other FVIII or vWF mutant
studies that cause other types of bleeding disorders. Researchers have often overlooked FVIII’s
interactions with other proteins in circulation, this new structural finding may serve a great
purpose in understanding other intricacies of FVIII in circulation. With better understanding of
FVIII and its other protein interactions, improved therapeutic strategies can subsequently be
made for patients who are suffering from FVIII or von Willebrand related disorders.
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Appendix A

Figure 1. Biolayer interferometry (BLI) binding signal representation (in triplicate) of G99:ET3i
complex against wild tyle TIL’E’. It was observed that wild type TIL’E’ did not associate well to
the AMC tip with a quick observable association and dissociation rate.

Figure 2. Biolayer interferometry (BLI) binding signal representation (in triplicate) of G99:ET3i
complex against R816Q. It was observed that there was a strong phase shift at stock R854Q
(highest) concentration in comparison to wild type. This association rate was observed in
quantitative data analysis.

Figure 3. Biolayer interferometry (BLI) binding signal representation (in triplicate) of G99:ET3i
complex against E787K mutant. Steady decrease in binding with decreasing concentrations of
mutant.
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Figure 4. Biolayer interferometry (BLI) binding signal representation (in triplicate) of G99:ET3i
complex against R854Q mutant. Similar visual representation compared to R816Q mutant.

Figure 5. Biolayer interferometry (BLI) binding signal representation (in triplicate) of G99:ET3i
complex against R782W mutant. It was observed that there was a strong phase shift at stock
R782W (highest) concentration like all TIL’E’ mutants with a quick change in poor signaling
upon lower concentrations of R782W.
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